- Federal agenciesIncreases access to fertility care (including IVF and preservation) for people covered by employer, individual, federal…
- WorkersCould expand demand for reproductive health providers, clinics, lab services, and associated supply chains, potentially…
- Federal agenciesStandardizes a national baseline for fertility benefits across many federal programs and insurance markets, reducing va…
Access to Fertility Treatment and Care Act
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Workforce, Oversight and Government Reform, Armed Services, an…
This bill (Access to Fertility Treatment and Care Act) requires group and individual health plans that cover obstetrical services to also cover a defined set of fertility treatments (including preservation of gametes/embryos, artificial insemination, assisted reproductive technology such as IVF, preimplantation genetic testing, fertility medications, and gamete donation). The requirement is incorporated into the Public Health Service Act, ERISA, and the Internal Revenue Code, and it extends parallel coverage rules to federal programs (FEHB, TRICARE, VA, Medicare) and conditions State Medicaid plans to cover fertility treatment consistent with the new standards.
Scope and mandate: liberals see expanded access as pro-equity; conservatives see an intrusive new insurance mandate and potential cost driver.
Relative to its intended legislative type, this bill is a comprehensive statutory effort to mandate fertility treatment coverage across private and multiple federal health programs, with clear definitions, cross‑statute amendments, and concrete implementation timelines but limited fiscal disclosure and limited explicit enforcement or measurement provisions.
This bill (Access to Fertility Treatment and Care Act) requires group and individual health plans that cover obstetrical services to also cover a defined set of fertility treatments (including preservation of gametes/embryos, artificial insemination, assisted reproductive technology such as IVF, preimplantation genetic testing, fertility medications, and gamete donation).
The requirement is incorporated into the Public Health Service Act, ERISA, and the Internal Revenue Code, and it extends parallel coverage rules to federal programs (FEHB, TRICARE, VA, Medicare) and conditions State Medicaid plans to cover fertility treatment consistent with the new standards.
The bill limits cost-sharing for fertility services so it cannot exceed the cost-sharing applied to other medical services, forbids incentives or contractual practices that discourage use of covered fertility services or limit provider discussion, and requires written notice to enrollees.
On content alone, the bill is important to a defined constituency (people seeking fertility care) and builds on existing state precedents and policy arguments for coverage parity, which could attract support. However, it is a sweeping federal mandate across multiple major programs with significant fiscal and implementation consequences and few offsets; it touches sensitive ethical issues and removes flexibility for many employers and plans. Those features historically make enactment harder absent broad bipartisan compromise or linkage to larger budget/health legislation.
Relative to its intended legislative type, this bill is a comprehensive statutory effort to mandate fertility treatment coverage across private and multiple federal health programs, with clear definitions, cross‑statute amendments, and concrete implementation timelines but limited fiscal disclosure and limited explicit enforcement or measurement provisions.
Scope and mandate: liberals see expanded access as pro-equity; conservatives see an intrusive new insurance mandate and potential cost driver.
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- Federal agenciesLikely increases health care spending for insurers and public programs (Medicare, Medicaid, TRICARE, FEHB, VA), which c…
- Potential burdenImposes regulatory and administrative burdens on insurers, plan administrators, and providers to implement new coverage…
- StatesMay create fiscal pressure on State Medicaid programs to expand covered services; although the bill allows timing relie…
Why the argument around this bill splits.
Scope and mandate: liberals see expanded access as pro-equity; conservatives see an intrusive new insurance mandate and potential cost driver.
A mainstream progressive would likely view this bill positively as a significant expansion of reproductive health access and equity.
They would note the inclusion of a wide range of fertility services (IVF, gamete preservation, embryo testing), coverage for veterans and people on Medicare/Medicaid, and protections against discriminatory denials as important gains.
They would appreciate the ban on incentives and provider gag rules and the parity on cost-sharing with obstetrical services.
A pragmatic moderate would generally see the bill as addressing an evident gap in reproductive health coverage and creating uniform national standards, but would be attentive to costs, administrative complexity, and implementation.
They would welcome explicit parity rules and protections against discriminatory practices, while wanting clearer fiscal estimates and guardrails to avoid large unintended premium increases or burdens on small employers.
They would also note the multiple program expansions (Medicare, Medicaid, TRICARE, VA, FEHB) raise questions about federal spending and intergovernmental implementation.
A mainstream conservative would likely oppose or be skeptical of the bill as an expansive federal insurance mandate that increases federal and private sector obligations.
Concerns would center on government overreach into employer plan design, the mandate’s effect on premiums and employer costs, and the extension of coverage into Medicare/Medicaid/TRICARE with uncertain fiscal consequences.
There would also be objections on moral or conscience grounds to coverage of procedures involving embryos, genetic testing, and gamete donation, and to the lack of explicit religious or conscience exemptions for providers or plans.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is important to a defined constituency (people seeking fertility care) and builds on existing state precedents and policy arguments for coverage parity, which could attract support. However, it is a sweeping federal mandate across multiple major programs with significant fiscal and implementation consequences and few offsets; it touches sensitive ethical issues and removes flexibility for many employers and plans. Those features historically make enactment harder absent broad bipartisan compromise or linkage to larger budget/health legislation.
- No cost estimate or budgetary offset is included in the bill text; the scale of federal and private spending impact is therefore unclear and could materially affect legislative support.
- The degree of stakeholder support or opposition (large insurers, employer coalitions, veterans' groups, military leadership, religious organizations, patient advocates) is unknown and would strongly influence committee and floor dynamics.
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Scope and mandate: liberals see expanded access as pro-equity; conservatives see an intrusive new insurance mandate and potential cost driv…
On content alone, the bill is important to a defined constituency (people seeking fertility care) and builds on existing state precedents a…
Relative to its intended legislative type, this bill is a comprehensive statutory effort to mandate fertility treatment coverage across private and multiple federal health programs, with clear definitions, cross‑statute…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.